OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback